revenu figur prior figur
pipelin track
messag report earn today came short jakafi
 consensu revenu partial driven inventori de-stock
narrow jakafi guidanc confirm object includ pemigatinib
regulatori file potenti jakafi label expans addit pivot trial readout
updat estim reflect financi result maintain neutral rate
jakafi sale street consensu jakafi revenu
guggenheim estim street estim attribut
revenu miss unexpect inventori chang follow jakafi recent price increas
explain histor inventori chang gradual predict post-
price action instead saw dramat steep inventory-rel loss
result rel flat qoq chang neg impact effect
negat report qoq growth jakafi patient mf pv rais
lower end jakafi guidanc previous
believ investor expect substanti rais guidanc link base
sale trajectori leav jakafi estim unchang
jakafi pdufa date steroid-refractori acut gvhd set feb snda
file accept base posit ph ii result present earlier
year show orr consist safeti profil jakafi ph trial also
steroid-refractori acut gvhd reach steroid-refractori chronic gvhd
on-going track pivot data estim market
patient addit timelin updat pivot ph trial itacitinib
provid treatment-nav acut gvhd expect produc pivot
data treatment nave chronic gvhd set begin
potenti itacitinib label could expand market opportun addit
patient global accord
ruxolitinib cream begin atop dermat potenti vitiligo pivot trial
ph ii result ruxolitinib cream atop dermat present
european academi dermatolog venerolog eadv show prompt yet
durabl improv easi iga itch state alreadi work fda
design pivot trial indic talk includ design factor number
patient dose whether activ compar need vitiligo ruxolitinib
cream current test on-going ph ii trial expect read
pend posit result pivot ph initi shortli afterward per
pemigatinib nda submiss cholangiocarcinoma track
present posit ph ii data esmo pemigatinib show
orr month month mo among metastat
cholangiocarcinoma icca patient believ pemigatinib well posit
new soc given competit advantag profil compar current soc
month howev given small elig patient popul estim
pemigatinib peak icca sale contribut overal valuat
larger pemigatinib-target market bladder cancer still evalu
amend protocol includ continu dose schedul similar
jnj nda-fil erdafitinib expect updat pemigatinib data
minor updat financi guidanc end cash
market secur debt manag slightli updat guidanc
narrow expens increas sg
expens use dcf valuat method
wacc termin growth believ trade fair market valu
maintain neutral rate
page analyst certif import disclosur
wacc consist commerci stage compani cover
well termin growth rate
 regulatori commerci setback
potenti emerg new competitor
lower product sale expect
potenti acquisit premium current valuat
page analyst certif import disclosur
chang fair valu acquisition-rel conting consider
interest incom net
unreal gains-to-loss long-term invest
incom tax
balanc sheet statement flow
guggenheim secur llc estim sec file
page analyst certif import disclosur
